<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23008736</PMID><DateCompleted><Year>2013</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1740-2530</ISSN><JournalIssue CitedMedium="Internet"><Volume>2012</Volume><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Clinical &amp; developmental immunology</Title><ISOAbbreviation>Clin Dev Immunol</ISOAbbreviation></Journal><ArticleTitle>Immunological evaluation and comparison of different EV71 vaccine candidates.</ArticleTitle><Pagination><StartPage>831282</StartPage><MedlinePgn>831282</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">831282</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) and coxsackievirus A16 (CVA16) are major causative agents of hand, foot, and mouth diseases (HFMDs), and EV71 is now recognized as an emerging neurotropic virus in Asia. Effective medications and/or prophylactic vaccines against HFMD are not available. The current results from mouse immunogenicity studies using in-house standardized RD cell virus neutralization assays indicate that (1) VP1 peptide (residues 211-225) formulated with Freund's adjuvant (CFA/IFA) elicited low virus neutralizing antibody response (1/32 titer); (2) recombinant virus-like particles produced from baculovirus formulated with CFA/IFA could elicit good virus neutralization titer (1/160); (3) individual recombinant EV71 antigens (VP1, VP2, and VP3) formulated with CFA/IFA, only VP1 elicited antibody response with 1/128 virus neutralization titer; and (4) the formalin-inactivated EV71 formulated in alum elicited antibodies that cross-neutralized different EV71 genotypes (1/640), but failed to neutralize CVA16. In contrast, rabbits antisera could cross-neutralize strongly against different genotypes of EV71 but weakly against CVA16, with average titers 1/6400 and 1/32, respectively. The VP1 amino acid sequence dissimilarity between CVA16 and EV71 could partially explain why mouse antibodies failed to cross-neutralize CVA16. Therefore, the best formulation for producing cost-effective HFMD vaccine is a combination of formalin-inactivated EV71 and CAV16 virions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Ai-Hsiang</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Vaccine R&amp;D Center, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Township, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chyi</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jui-Yuan</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Lien</LastName><ForeName>Shu-Pei</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Meng-Shin</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Tasi</LastName><ForeName>Hau-Pong</ForeName><Initials>HP</Initials></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Kuang-Nan</ForeName><Initials>KN</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shih-Jen</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Sia</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Suh-Chin</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Min-Shi</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Chia-Hsin</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jen-Ren</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Yen-Hung</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>Clin Dev Immunol</MedlineTA><NlmUniqueID>101183692</NlmUniqueID><ISSNLinking>1740-2522</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015678">Viral Structural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012208" MajorTopicYN="N">Rhabdomyosarcoma</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015678" MajorTopicYN="N">Viral Structural Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23008736</ArticleId><ArticleId IdType="pmc">PMC3447357</ArticleId><ArticleId IdType="doi">10.1155/2012/831282</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. The New England Journal of Medicine. 1999;341(13):929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiology Reviews. 2002;26(1):91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine. 2010;28(20):3516&#x2013;3521.</Citation><ArticleIdList><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Review of Vaccines. 2010;9(2):149&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">20109026</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. The Lancet Infectious Diseases. 2010;10(11):778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang ML, Ho MS, Lee MS. Enterovirus 71 vaccine: when will it be available? Journal of the Formosan Medical Association. 2011;110:425&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">21742245</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. Journal of Infectious Diseases. 1974;129(3):304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26(15):1855&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Research. 1995;39(2-3):195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Bible JM, Iturriza-Gomara M, Megson B, et al. Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. Journal of Clinical Microbiology. 2008;46(10):3192&#x2013;3200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566106</ArticleId><ArticleId IdType="pubmed">18650362</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan YF, Sam IC, Abubakar SC. Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infection, Genetics and Evolution. 2010;10(3):404&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">19465162</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Hsu YW, Smith DJ, et al. Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. Journal of Clinical Microbiology. 2009;47(11):3653&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamanti E, Ibrahimi B, Tafaj F, et al. Surveillance of suspected poliomyelitis in Albania, 1980-1995: suggestion of increased risk of vaccine associated poliomyelitis. Vaccine. 1998;16(9-10):940&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pubmed">9682341</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. The Lancet. 2001;358(9276):121&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">11463415</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20(5-6):895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Lian WC, Butler M, Wu SC. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine. 2007;25(1):19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16919374</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genetic Vaccines and Therapy. 2007;5, article 6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JY, Chang CP, Tsai HHP, et al. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine. 2012;30(4):703&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">22142585</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chang HW, Yang G, et al. Development of a quantitative enzyme linked immunosorbent assay for monitoring the EV71 vaccine manufacturing process. Journal of Virological Methods. 2011;176(1-2):60&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">21704080</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29(26):4362&#x2013;4372.</Citation><ArticleIdList><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology. 1938;27(3):493&#x2013;497.</Citation></Reference><Reference><Citation>Liu CC, Guo MS, Lin FHY, et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS ONE. 2011;6(5)e20005</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Panezutti H, James O, Hansen EJ, et al. Identification of surface-exposed B-cell epitopes recognized by Haemophilus influenzae type b P1-specific monoclonal antibodies. Infection and Immunity. 1993;61(5):1867&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280777</ArticleId><ArticleId IdType="pubmed">7682997</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DGW, Alonso S, Phoon MC, Ramachandran NP, Chow VTK, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Research. 2007;125(1):61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DGW, Alonso S, Chow VTK, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes and Infection. 2007;9(11):1299&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;28(46):7444&#x2013;7451.</Citation><ArticleIdList><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Roaldao A, Mellado MCM, Castiho LR, Corrondo MJT, Alves PM. Virus-like particles in vaccine development. Expert Review of Vaccines. 2010;9:1149&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">20923267</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Cao RY, Deng YQ, et al. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virology Journal. 2011;8, article 106</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060144</ArticleId><ArticleId IdType="pubmed">21385398</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Chen IC, Su LY, Huang KJ, Lei HY, Liu CC. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clinical and Vaccine Immunology. 2010;17(10):1517&#x2013;1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953001</ArticleId><ArticleId IdType="pubmed">20685937</ArticleId></ArticleIdList></Reference><Reference><Citation>Bek EJ, Hussain KM, Phuektes P, et al. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine. 2011;29(29-30):4829&#x2013;4838.</Citation><ArticleIdList><ArticleId IdType="pubmed">21550375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Liu L, Zhao H, et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine. 2011;29:6269&#x2013;6275.</Citation><ArticleIdList><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>